Retinal Vein Occlusion

Overview of branch retinal vein occlusion and central retinal vein occlusion.

What is a Retinal Vein Occlusion?

Arteries bring blood to the eye and veins bring blood back to the heart. While arteries have tough walls which usually become harder with age, veins have thin walls which remain pliant and soft throughout life. Because of the anatomy of the eye, the retinal veins are prone to occlusion. There are two main locations where retinal veins are occluded. One is at the crossing of a retinal arteriole and branch retinal vein. An occlusion at a crossing of a branch retinal arteriole and branch retinal vein causes a branch retinal vein occlusion. The second is at the main trunk of the retinal vein where it leaves the eye through the optic nerve. An occlusion at the main trunk of the retinal vein causes a central retinal vein occlusion. The picture shows a photo with dilated veins and retinal hemorrhages from a fresh central retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The retinal veins dilate and their are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen. Monthly examinations of pateints with CRVO for less than six months are very important. Some patients with CRVO and very bad circulation, develop a severe type of glaucoma. In this situation, the eye becomes red and painful and without treatment, total visual loss can occur rapidly. If an examining doctor sees early signs that this complication may occur, then laser treatment can sometimes protect the eye. Once the pressure rise occurs, surgery can be helpful.

Read more

Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Retinal Vein Occlusion

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

MD Magazine

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses
MD Magazine
New research suggests disorganization of retinal inner layers (DRIL) could be a biomarker for visual acuity and treatment prognosis among patients with retinal vein occlusion (RVO). The findings are based on a retrospective study of 147 patients with ...


Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual ...
Associated Press (press release)
A total of four cases of uncomplicated Herpes zoster occurred in the filgotinib arms, and one non-serious case of retinal vein occlusion was reported in the filgotinib 200 mg group. Two major adverse cardiovascular events were reported, one in the ...


Specialist shares key messages of Euretina guidelines for management of RVO
Healio
VIENNA — A thorough ocular examination, early treatment and a timely switch of nonresponders are key for successful management of retinal vein occlusion, according to a specialist reporting on the Euretina guidelines for the management of retinal disease.


RVC (Retinal Vein Occlusion) Market 2018 Superior Growth at a CAGR of 11.2% till 2023 | Diagnosis, Optical ...
MENAFN.COM
(MENAFN Editorial) 'Global Retinal Vein Occlusion Market' Report of MRFR Displaying an Overall Business Analysis, Top Participants, Worldwide Segmentation with sub Segments. And market is set to expand at 11.2% of CAGR by 2023. Retinal Vein ...

and more »

Treat-and-extend regimen reduces injection burden in macular edema secondary to CRVO
Healio
A phase IV study to assess efficacy and safety of a treat-and-extend regimen of aflibercept for treatment of macular edema secondary to central retinal vein occlusion in naïve patients. NEUTON study. Presented at: Euretina; Sept. 20, 2018; Vienna ...


Business Wire (press release)

Altris.AI – The New Era of Retinal Diagnosis is Coming
Business Wire (press release)
Lamellar Macular Hole;. • Pseudohole;. • Central Retinal Vein Occlusion;. • Branch Retinal Vein Occlusion;. • Retinal Artery Occlusion;. • Pigment Choroidal Nevus;. • Solar Maculopathy;. • Chorioretinal scars;. • Vitelliform Dystrophy;. • Tapetoretinal ...

and more »

Fairfield Current

Regeneron Pharmaceuticals Inc (REGN) Stake Lowered by Tiaa Fsb
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals, Inc. (REGN) Analysts See $5.03 EPSThe Cardinal Weekly (press release)
SEC FORM 4 - SEC.govSEC.gov

all 52 news articles »

Global Retinal Vein Occlusions market – industry analysis, share, growth, trends and forecast from 2018-2025
Trade Market Research
The Retinal Vein Occlusions Market report covers the present and past market scenarios, market development patterns, and is likely to proceed with a continuing development over the forecast period. The Global Retinal Vein Occlusions Market research ...


Apex News

Retinal Vein Occlusion Pipeline Therapeutics Research and Development 2018
Apex News
The Retinal Vein Occlusion pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

and more »

MedicalResearch.com (blog)

Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-VGEF Therapy for Macular ...
MedicalResearch.com (blog)
Given this association, the research group at Cole Eye Institute studied how DRIL may affect VA outcomes in patients with retinal vein occlusion (RVO) undergoing treatment for secondary macular edema. DRIL is defined as the extent to which there is a ...


Allergan to Showcase Continued Eye Care Innovation with New Data on Investigational Medicines at the American ...
PR Newswire (press release)
... has launched over 125 eye care products and invested billions of dollars in new treatments for the most prevalent eye conditions including glaucoma, ocular surface disease, and retinal diseases such as diabetic macular edema and retinal vein occlusion.

and more »

Fairfield Current

Clearside Biomedical Appoints Veteran Supply Chain Executive, Thomas Crawford, as Vice President, Supply Chain
P&T Community
Clearside's pipeline includes advanced and pre-clinical product candidates in diseases where macular edema is a common complication, including uveitis, retinal vein occlusion (“RVO”) and diabetic macular edema (“DME”). Clearside's most advanced ...
Clearside Biomedical (CLSD) Stock Price Down 6.8%Fairfield Current

all 10 news articles »

FDA Headlines

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Duplixant Data Came at Just the Right Time
FDA Headlines
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Ophthalmology Times (press release) (blog)

When autoimmune diseases exert neuro-ophthalmic effects
Ophthalmology Times (press release) (blog)
... retinal vasculitis, retinal vein occlusions, retinal artery occlusions, secondary pseudotumor cerebri, and symptoms such as amaurosis fugax. Numerous reports of autoimmune diseases associated with these pathologies have been described (see Table 1).


IDA Report

Retinal Vein Occlusion Therapeutics Market: Emerging Trends, Highlights and Challenges Forecast 2023
IDA Report
Retinal Vein Occlusion Therapeutics Market Report analysts present the various facets of the market a detailed picture of the market by way of study, synthesis, and summation with a special focus on identifying the key industry influencers. The report ...


$5.22 EPS Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarter
BharataPress
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.


PR Web (press release)

Retina Group of New York Sponsors Juvenile Diabetes Research Foundation (JDRF) ONE WALK Heckscher State ...
PR Web (press release)
The practice is limited to medical and surgical retinal problems. These commonly include diabetic retinopathy, macular degeneration, retinal vein occlusion, retinal detachment, macula pucker, macula hole, cataract surgery complications, uveitis ...

and more »

Clearside Biomedical (NASDAQ:CLSD) Stock Rating Lowered by Zacks Investment Research
Fairfield Current
Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related ...

and more »

FDA Headlines

Is it Time to Get Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on the Radar Again?
FDA Headlines
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Baseball Daily News

11485 Shares in Clearside Biomedical Inc (CLSD) Acquired by Voya Investment Management LLC
Baseball Daily News
... suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and ...
Clearside Biomedical (CLSD) Lowered to “Sell” at Zacks Investment ResearchXNewsPress

all 8 news articles »

Chronicle India

Global Retinal Vein Occlusion Therapeutics Market 2018 : Healthcare Analysis and Clinical Review- 2023
Chronicle India
The Global Retinal Vein Occlusion Therapeutics Market Report 2018 stretches out accurate and descriptive details through the range of years 2018-2023. The report comprises interior and outside exploration and bits of comprehension of Retinal Vein ...


Mirati Therapeutics (MRTX) and OHR Pharmaceutical (NASDAQ:OHRP) Critical Analysis
BharataPress
The company is evaluating Squalamine in combination with Lucentis injections, which completed Phase II clinical trials for the treatment of retinal diseases, including wet form of age-related macular degeneration, retinal vein occlusion, and diabetic ...


Gulf Today

'Eyes are windows to systematic health of a person'
Gulf Today
Diabetic Retinopathy – damaged retina blood vessels due to high blood sugar levels. * Retinal Vein Occlusion related to high blood pressure – eye stroke. * Keratoconus – progressive thinning of the cornea. * Congenital cataract – cloudy eye lens of the ...

and more »

Cystic Fibrosis News Today

CF Patients at Greater Risk for Occlusions in Retinal Vessels, Case Report Suggests
Cystic Fibrosis News Today
Patients with cystic fibrosis (CF) have a greater risk of developing abnormalities in their retinal veins, which can impair visual acuity, a case report suggests. But researchers claim the higher risk is not due to one single factor, but to several ...


Korea Biomedical Review

Allergan's eye implant recalled due to foreign substance
Korea Biomedical Review
Ozurdex is implanted in the vitreous of the eye to treat macular edema following branch retinal vein occlusion (BRVO), diabetic macular edema, and noninfectious uveitis with inflammation of the posterior segment of the eye. Recalled products have ...


Public Employees Retirement System of Ohio Purchases 223 Shares of Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Hold Rating from JPMorgan Chase & Co.
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov

all 46 news articles »

Two-year data confirm efficacy of EYLEA® (aflibercept solution for injection) Treat and Extend dosing regimens for ...
PharmiWeb.com (press release)
... visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO) and visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO); visual impairment due to diabetic macular oedema (DMO) and ...


Thorold News

Regeneron Pharmaceuticals (REGN) Price Target Increased to $410.00 by Analysts at Canaccord Genuity
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Quarterly Sentiment Change ReportThorold News

all 44 news articles »

Clearside Biomedical (CLSD) Stock Rating Lowered by Zacks Investment Research
BharataPress
Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related ...

» Load more